Top Markets
Coin of the day
InNexus Biotechnology, Inc. InNexus Biotechnology, Inc.

InNexus Biotechnology, Inc.

IXSBF
Rang in aandelen #41697
InNexus Biotechnology, Inc. is a development-stage company dedicated to... InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.
Aandeelprijs
$0.0001
Laatst gesynchroniseerd: 2025-11-07
Marktkapitalisatie
$12.63K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
CA
Handel InNexus Biotechnology, Inc. (IXSBF)

Categorie

Aandelsplitsingen voor InNexus Biotechnology, Inc. (IXSBF)
Het aandeel InNexus Biotechnology, Inc. (symbool: IXSBF) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Aug 13, 2026.
Eén aandeel IXSBF dat vóór Aug 13, 2026 werd gekocht, staat nu gelijk aan 0 aandelen IXSBF.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten